WO2008096755A1 - Inhibiteur du récepteur vanilloïde (vr1) et son utilisation - Google Patents

Inhibiteur du récepteur vanilloïde (vr1) et son utilisation Download PDF

Info

Publication number
WO2008096755A1
WO2008096755A1 PCT/JP2008/051865 JP2008051865W WO2008096755A1 WO 2008096755 A1 WO2008096755 A1 WO 2008096755A1 JP 2008051865 W JP2008051865 W JP 2008051865W WO 2008096755 A1 WO2008096755 A1 WO 2008096755A1
Authority
WO
WIPO (PCT)
Prior art keywords
dibenzo
compound
inhibitor
vanilloid receptor
hydroxy groups
Prior art date
Application number
PCT/JP2008/051865
Other languages
English (en)
Japanese (ja)
Inventor
Kazuharu Takeuchi
Takaaki Okita
Hiroko Miyahara
Original Assignee
Nippon Suisan Kaisha, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Suisan Kaisha, Ltd. filed Critical Nippon Suisan Kaisha, Ltd.
Publication of WO2008096755A1 publication Critical patent/WO2008096755A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)

Abstract

La présente invention concerne un nouvel inhibiteur du récepteur vanilloïde (VR1) qui peut être utilisé en tant qu'agent thérapeutique efficace pour une douleur aiguë et/ou une douleur chronique qui a moins d'effets secondaires indésirables et peut être utilisé sans risque. L'inhibiteur du récepteur vanilloïde (VR1) comprend au moins un membre choisi parmi un composé de dibenzo[b,f]thiépine ayant au moins deux groupes hydroxy, un composé de dibenzo[b,f]oxépine ayant au moins deux groupes hydroxy et des sels acceptables sur le plan pharmaceutique des composés en tant que principe actif. De préférence, dans le composé de dibenzo[b,f]thiépine ou le composé de dibenzo[b,f]oxépine, deux groupes hydroxy sont localisés sur un cycle benzène dans une configuration résorcinol.
PCT/JP2008/051865 2007-02-07 2008-02-05 Inhibiteur du récepteur vanilloïde (vr1) et son utilisation WO2008096755A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007028534 2007-02-07
JP2007-028534 2007-02-07

Publications (1)

Publication Number Publication Date
WO2008096755A1 true WO2008096755A1 (fr) 2008-08-14

Family

ID=39681663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051865 WO2008096755A1 (fr) 2007-02-07 2008-02-05 Inhibiteur du récepteur vanilloïde (vr1) et son utilisation

Country Status (1)

Country Link
WO (1) WO2008096755A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029995A1 (fr) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 Agent thérapeutique contre la douleur
WO2010029996A1 (fr) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 Composition pharmaceutique

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5495583A (en) * 1977-12-13 1979-07-28 Hoechst Ag Aminoalkylthiodibenz oxepins and their precursor
JPS5498794A (en) * 1977-12-13 1979-08-03 Hoechst Ag Aminoalkyl thiodibenz thiepine compound
JPS54122284A (en) * 1978-02-17 1979-09-21 Dainippon Pharmaceut Co Ltd Dibenzb,foxepin derivative
JPS55153782A (en) * 1979-05-17 1980-11-29 Dainippon Pharmaceut Co Ltd Dibenzo (b,f) thiepin derivative
WO1996025927A1 (fr) * 1995-02-22 1996-08-29 Nippon Suisan Kaisha, Ltd. Inhibiteur des recepteurs de l'acide glutamique et ameliorant des fonctions cerebrales
WO1997025985A1 (fr) * 1996-01-19 1997-07-24 Nippon Suisan Kaisha, Ltd. Relaxant des muscles lisses de la trachee
JP2003533528A (ja) * 2000-05-17 2003-11-11 プリバ フアルマセウトスカ インダストリヤ デイオニツコ ドルストヴオ 腫瘍壊死因子抑制剤としてのチエノベンゾアズレン化合物
WO2005046683A1 (fr) * 2003-10-07 2005-05-26 Renovis, Inc. Derives d'amide utilises comme ligands du canal ionique et compositions pharmaceutiques et methodes d'utilisation de ces derives
WO2005072681A2 (fr) * 2004-01-23 2005-08-11 Amgen Inc. Ligands des recepteurs vanilloides et utilisation de ceux-ci dans divers traitements
JP2005524717A (ja) * 2002-05-08 2005-08-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト ヒドロキシテトラヒドロ−ナフタレニル尿素誘導体
WO2006010587A1 (fr) * 2004-07-24 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes actifs sur le recepteur sigma pour le traitement de l'allodynie mecanique
WO2006075255A2 (fr) * 2005-01-13 2006-07-20 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugues de macrolides anti-inflamatoires
WO2006124753A2 (fr) * 2005-05-12 2006-11-23 Amgen Inc. Traitement avec un agent antipyretique, de l'elevation de la temperature corporelle induite par l'antagoniste vr1

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5495583A (en) * 1977-12-13 1979-07-28 Hoechst Ag Aminoalkylthiodibenz oxepins and their precursor
JPS5498794A (en) * 1977-12-13 1979-08-03 Hoechst Ag Aminoalkyl thiodibenz thiepine compound
JPS54122284A (en) * 1978-02-17 1979-09-21 Dainippon Pharmaceut Co Ltd Dibenzb,foxepin derivative
JPS55153782A (en) * 1979-05-17 1980-11-29 Dainippon Pharmaceut Co Ltd Dibenzo (b,f) thiepin derivative
WO1996025927A1 (fr) * 1995-02-22 1996-08-29 Nippon Suisan Kaisha, Ltd. Inhibiteur des recepteurs de l'acide glutamique et ameliorant des fonctions cerebrales
WO1997025985A1 (fr) * 1996-01-19 1997-07-24 Nippon Suisan Kaisha, Ltd. Relaxant des muscles lisses de la trachee
JP2003533528A (ja) * 2000-05-17 2003-11-11 プリバ フアルマセウトスカ インダストリヤ デイオニツコ ドルストヴオ 腫瘍壊死因子抑制剤としてのチエノベンゾアズレン化合物
JP2005524717A (ja) * 2002-05-08 2005-08-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト ヒドロキシテトラヒドロ−ナフタレニル尿素誘導体
WO2005046683A1 (fr) * 2003-10-07 2005-05-26 Renovis, Inc. Derives d'amide utilises comme ligands du canal ionique et compositions pharmaceutiques et methodes d'utilisation de ces derives
WO2005072681A2 (fr) * 2004-01-23 2005-08-11 Amgen Inc. Ligands des recepteurs vanilloides et utilisation de ceux-ci dans divers traitements
WO2006010587A1 (fr) * 2004-07-24 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Utilisation de composes actifs sur le recepteur sigma pour le traitement de l'allodynie mecanique
WO2006075255A2 (fr) * 2005-01-13 2006-07-20 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugues de macrolides anti-inflamatoires
WO2006124753A2 (fr) * 2005-05-12 2006-11-23 Amgen Inc. Traitement avec un agent antipyretique, de l'elevation de la temperature corporelle induite par l'antagoniste vr1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010029995A1 (fr) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 Agent thérapeutique contre la douleur
WO2010029996A1 (fr) * 2008-09-11 2010-03-18 協和発酵キリン株式会社 Composition pharmaceutique

Similar Documents

Publication Publication Date Title
EP2963031A3 (fr) Promédicaments de tétrahydrocannabinol, compositions contenant des promédicaments de tétrahydrocannabinol et méthodes d'utilisation de celles-ci
WO2009017837A3 (fr) Aérosol sublingual de fentanyl
WO2005117895A8 (fr) Compositions contenant de la meloxicame
WO2008020040A3 (fr) Utilisation de composés et de dérivés de 2,5-dihydroxybenzène pour le traitement de la fibrose
GT200800143A (es) Derivados de pirimidina utilizados como inhibidores de cinasa pi-3
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
WO2006098761A3 (fr) Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
WO2007084728A3 (fr) 2-imino-benzimidazoles
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
WO2005123134A3 (fr) Systeme d'administration a liberation controlee pour metformine
WO2007109288A3 (fr) R-étifoxine énantiomériquement pure, ses compositions pharmaceutiques et procédés de leur utilisation
WO2006008173A3 (fr) Formulations pharmaceutiques
WO2007136741A3 (fr) N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
WO2007050353A3 (fr) Methodes de traitement utilisant des agonistes du recepteur d'oxytocine
MX2010001243A (es) Composicion anti-inflamatoria.
EP1440689A3 (fr) Traitement des troubles neurotiques
WO2008039406A3 (fr) Formulations lyophilisées à délitement rapide d'un antagoniste du récepteur de la thrombine
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
WO2007126898A8 (fr) Utilisation de ladostigil pour le traitement de la schizophrénie
WO2005091987A3 (fr) Methode permettant de traiter le syndrome de down

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710797

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08710797

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP